{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022205","form_type":"8-K","ticker":"SNES","cik":"0001680378","company_name":"SenesTech, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.557127+00:00","generated_at":"2026-06-02T06:21:44.660337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SenesTech Q1 revenue $415K record, up 78% YoY; Evolve drives >50% of sales","bullets":["Q1 2024 revenue $415,000, up 78% from $233,000 in Q1 2023; record quarterly revenue.","Net loss narrowed to $1.8M from $2.0M; adjusted EBITDA loss $1.7M vs $1.8M.","Evolve soft bait accounted for >50% of Q1 revenue; became biggest-selling product.","Launched Evolve Mouse in May 2024; extended distribution to Amazon, rep groups, 4,500 retail locations.","Cash at March 31, 2024 was $3.6M; New York City Council proposed deploying EPA-approved rat birth control."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022205","json":"https://secwatch.observer/filing/0001628280-24-022205.json","markdown":"https://secwatch.observer/filing/0001628280-24-022205.md","text":"https://secwatch.observer/filing/0001628280-24-022205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/0001628280-24-022205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/snes-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:21:44.660337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8cb8f54e483e96706b4df3ca53794047fb311ea","claim":"SenesTech, Inc. reported first quarter ended March 31, 2024 results: revenue $415,000, net income $1.8 million.","evidence_excerpt":"EPA-registered Rat Birth Control ® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • EvolveTM, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/0001628280-24-022205-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$415,000"},{"label":"Net income","value":"$1.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}